Selvita has two primary focus areas: to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services, and as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.
The company was established in 2007 and currently employs over 360 scientists, among which 30% are PhDs.
- Contract chemistry services
- Biology services
- Integrated drug discovery projects
- Comparative studies of biosimilar medicinal products
Selvita’s laboratories are located in Krakow, Poland and have GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe.
Selvita has been listed on the Main Market of Warsaw Stock Exchange (WSE:SLV) since December 2014.